(Q45866922)

English

Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).

scientific article published on 7 February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008). (English)

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

E J Neufeld

1

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

C M Kessler

2

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

J C Gill

3

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

C T Wilke

4

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

D L Cooper

5

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

Htrs Investigators

6

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

publication date

7 February 2011

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

17

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

4

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

650-656

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Recombinant factor VIIa in the treatment of bleeding

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Platelet activity of high-dose factor VIIa is independent of tissue factor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2010.02483.X

21 January 2018

Identifiers

10.1111/J.1365-2516.2010.02483.X

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21299750

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45866922&oldid=1320372571"